Investing Profile

Cillian King

VCInvestor
Managing Director at EQT Life Sciences
eqtgroup.com/about/people/cil...Amsterdam, Netherlands
Photo of Cillian King, Managing Director at EQT Life Sciences

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Massachusetts Institute of Technology (MIT) Network
12 CONNECTIONS
cb
EQT Life Sciences Managing Director
$11.0M - $65.0M
$25.0M
1
€260M
CompanyStageDateRound SizeTotal Raised
QurAlis
Series BMar 2023$88M
$140M
Co-investors: Amy Schulman (Polaris Partners), Jeffrey Moore (MP Healthcare Venture Management), Johannes Fruehauf (Mission BioCapital), Philip Scheltens (EQT Life Sciences), Roel Bulthuis (INKEF Capital), Laia Crespo (Sanofi Ventures), Stephen Thompson (Brandon Capital Partners)
Board Member QurAlis2023 - Present
Managing Director EQT Group2022 - Present
Board Member Muna Therapeutics2021 - Present
Board Member Sairopa B.V.2021 - Present
Founder Koala Life Sciences2017 - Present
Investment Manager EQT Group2021 - 2022
Board Member Pan Cancer T2020 - 2021
Board Member Allero Therapeutics2019 - 2021
Investment Manager Swanbridge Capital2018 - 2021
Team leader | Life Sciences Catalyze - Carrying Ideas Forward2015 - 2017
Research Fellow Massachusetts Institute of Technology (MIT)2009 - 2009
Intern CNCR, Center for Neurogenomics & Cognitive Research2008 - 2008
BioBusiness Summer School
Vrije Universiteit Amsterdam (VU Amsterdam) Doctor of Philosophy - PhD Molecular Neurosciences